Boldenone Undecylenate

Dehydrotestosterone — testosterone analogue with an added 1,2-double bond. AR binding is measurable but lower than parent testosterone; the clinically interesting feature is upregulation of erythropoietin production, producing hematocrit drift steeper than any other injectable AAS. Bloodwork pattern: HCT climbs 6–8 percentage points over a 16-week run without compensatory caloric intake changes. Erythrocytosis is the rate-limiting variable, not androgen dose. Aromatisation is low (~half testosterone rate) but estradiol creep occurs on long cycles — AI requirement is patient-specific rather than protocol-wide. Undecylenate ester: 14-day half-life and predictable weekly dosing. Appetite stimulation is direct (hypothalamic NPY pathway) and begins within 2 weeks of protocol initiation.